Cowen analyst Boris Peaker lowered the firm’s price target on Pacira to $50 from $54 and keeps a Market Perform rating on the shares. The analyst decreased his 4Q and 2022 Exparel estimates following disappointing October and November monthly sales and he believes Exparel sales will continue to grow at mid-single digit rate.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PCRX:
- Pacira sinks after continuing to not provide outlook with monthly sales
- Pacira reports preliminary net product sales of $57.5M for November
- Paulson adds Rumble, exits Occidental in Q3
- Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022
- Pacira BioSciences to Present at Two Healthcare Conferences in November